Shares of Enliven Therapeutics surged up to 60% after the company reported positive Phase 1b data for ELVN-001 in chronic myeloid leukemia patients. The drug showed strong efficacy across multiple doses with a favourable safety profile in heavily pre-treated patients. Enliven plans to present more data in 2026 and launch a Phase 3 trial later that year.